|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chornokur G, Amankwah EK, Schildkraut JM
and Phelan CM: Global ovarian cancer health disparities. Gynecol
Oncol. 129:258–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lowe KA, Chia VM, Taylor A, O'Malley C,
Kelsh M, Mohamed M, Mowat FS and Goff B: An international
assessment of ovarian cancer incidence and mortality. Gynecol
Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin
MC, You SL, Cheng WF and Lai MS: Trends in incidence and survival
outcome of epithelial ovarian cancer: 30-year national
population-based registry in Taiwan. J Gynecol Oncol. 24:342–351.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wong KH, Mang OW, Au KH and Law SC:
Incidence, mortality, and survival trends of ovarian cancer in Hong
Kong, 1997 to 2006: A population-based study. Hong Kong Med J.
18:466–474. 2012.PubMed/NCBI
|
|
6
|
Ledermann JA, Raja FA, Fotopoulou C,
Gonzalez-Martin A, Colombo N and Sessa C: ESMO Guidelines Working
Group: Newly diagnosed and relapsed epithelial ovarian carcinoma:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24 Suppl 6:vi24–vi32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katz B, Trope CG, Reich R and Davidson B:
MicroRNAs in ovarian cancer. Hum Pathol. 46:1245–1256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davis-Dusenbery BN and Hata A: MicroRNA in
Cancer: The involvement of aberrant microRNA biogenesis regulatory
pathways. Genes Cancer. 1:1100–1114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tutar L, Tutar E and Tutar Y: MicroRNAs
and cancer; an overview. Curr Pharm Biotechnol. 15:430–437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xia H, Ooi LL and Hui KM: MiR-214 targets
β-catenin pathway to suppress invasion, stem-like traits and
recurrence of human hepatocellular carcinoma. PLoS One.
7:e442062012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bar-Eli M: Searching for the
‘melano-miRs’: miR-214 drives melanoma metastasis. EMBO J.
30:1880–1881. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Penna E, Orso F, Cimino D, Tenaglia E,
Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De
Pittà C, et al: microRNA-214 contributes to melanoma tumour
progression through suppression of TFAP2C. EMBO J. 30:1990–2007.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu Z and Wang T: miR-214 promotes the
proliferation and invasion of osteosarcoma cells through direct
suppression of LZTS1. Biochem Biophys Res Commun. 449:190–195.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Z, Chen S, Luan X, Li Y, Liu M, Li X,
Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical
cancers and inhibits the growth of HeLa cells. IUBMB Life.
61:1075–1082. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gadducci A, Sergiampietri C, Lanfredini N
and Guiggi I: Micro-RNAs and ovarian cancer: The state of art and
perspectives of clinical research. Gynecol Endocrinol. 30:266–271.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bai H, Li H, Li W, Gui T, Yang J, Cao D
and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of
distinct invasive and migratory capacities in human ovarian cancer
cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X, Cheng Y, Li P, Tao J, Deng X,
Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21
diminishes aerobic glycolysis in bladder cancer T24 cells via the
PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
FIGO Oncology Committee, . FIGO staging
for gestational trophoblastic neoplasia 2000. FIGO Oncology
Committee. Int J Gynaecol Obstet. 77:285–287. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scully RE and Sobin LH: Histological
Typing of Ovarian Tumours. 2nd. Springer Verlag; New York, NY:
1999, View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Penna E, Orso F and Taverna D: miR-214 as
a key hub that controls cancer networks: Small player, multiple
functions. J Invest Dermatol. 135:960–969. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vara Fresno JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Zeng J and Shen K: PI3K/AKT/mTOR
signaling pathway as a therapeutic target for ovarian cancer. Arch
Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiang R, Wang F, Shi LY, Liu M, Chen S,
Wan HY, Li YX, Li X, Gao SY, Sun BC and Tang H: Plexin-B1 is a
target of miR-214 in cervical cancer and promotes the growth and
invasion of HeLa cells. Int J Biochem Cell Biol. 43:632–641. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yin G, Chen R, Alvero AB, Fu HH, Holmberg
J, Glackin C, Rutherford T and Mor G: TWISTing stemness,
inflammation and proliferation of epithelial ovarian cancer cells
through MIR199A2/214. Oncogene. 29:3545–3553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou J and Werb Z: MicroRNAs play a big
role in regulating ovarian cancer-associated fibroblasts and the
tumor microenvironment. Cancer Discov. 2:1078–1080. 2012.
View Article : Google Scholar : PubMed/NCBI
|
